We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRCT icon
76
Procept Biorobotics
PRCT
$1.07B
$24.4M 0.35%
589,262
-6,118
-1% -$244K
ADPT icon
77
Adaptive Biotechnologies
ADPT
$3.5B
$23.4M 0.34%
3,279,620
-259,435
-7% -$2.44M
AXSM icon
78
Axsome Therapeutics
AXSM
$11.7B
$22.2M 0.32%
496,524
-320,617
-39% -$16M
CVS icon
79
CVS Health
CVS
$137B
$21.5M 0.31%
225,114
-4,039
-2% -$400K
COO icon
80
Cooper Companies
COO
$13.9B
$21.5M 0.31%
325,252
-664
-0.2% -$50.9K
AUPH icon
81
Aurinia Pharmaceuticals
AUPH
$1.98B
$21.4M 0.31%
2,846,457
+175,044
+7% +$1.52M
BNTX icon
82
BioNTech
BNTX
$23.4B
$20.7M 0.3%
153,580
+2,380
+2% +$364K
GBIO
83
DELISTED
Generation Bio
GBIO
$19.3M 0.28%
362,728
– –
HZNP
84
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$18.7M 0.27%
301,850
-35,584
-11% -$2.49M
RMD icon
85
ResMed
RMD
$28.6B
$18.5M 0.27%
84,612
-253
-0.3% -$57.6K
PRVA icon
86
Privia Health
PRVA
$3.34B
$17.5M 0.25%
515,030
-4,846
-0.9% -$179K
BAX icon
87
Baxter International
BAX
$11.5B
$17.2M 0.25%
319,548
-138,271
-30% -$8.32M
PHR icon
88
Phreesia
PHR
$655M
$17M 0.24%
666,419
-13,734
-2% -$343K
ILMN icon
89
Illumina
ILMN
$28B
$16.4M 0.24%
88,333
-966
-1% -$191K
WVE icon
90
Wave Life Sciences
WVE
$1.11B
$16.2M 0.23%
4,494,458
– –
HOLX
91
DELISTED
Hologic
HOLX
$16.2M 0.23%
251,412
-19,413
-7% -$1.34M
HCM icon
92
HUTCHMED
HCM
$1.93B
$15.9M 0.23%
1,758,075
+1,768
+0.1% +$22.2K
ALGN icon
93
Align Technology
ALGN
$12.7B
$15.5M 0.22%
74,939
-60,301
-45% -$15.5M
SRRK icon
94
Scholar Rock
SRRK
$6.27B
$14.9M 0.21%
2,152,025
– –
NVRO
95
DELISTED
NEVRO CORP.
NVRO
$12.2M 0.17%
260,835
-4,504
-2% -$209K
REGN icon
96
Regeneron Pharmaceuticals
REGN
$70.9B
$12M 0.17%
17,389
-338
-2% -$213K
EPIX
97
DELISTED
ESSA Pharma
EPIX
$10.7M 0.15%
5,898,583
+888,869
+18% +$2.34M
AMGN icon
98
Amgen
AMGN
$197B
$10.2M 0.15%
45,196
-5,763
-11% -$1.4M
TDOC icon
99
Teladoc Health
TDOC
$1.7B
$9.89M 0.14%
390,286
-25,826
-6% -$906K
AVTR icon
100
Avantor
AVTR
$7.37B
$9.86M 0.14%
503,007
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.